These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994 [TBL] [Abstract][Full Text] [Related]
4. Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing. Shin DW; Kim SM; Kim JA; Park HS; Hwang SM; Im K; Kim S; Kim J; Kwon S; Yoon SS; Lee DS Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e496-e505. PubMed ID: 31221512 [TBL] [Abstract][Full Text] [Related]
5. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Xu L; Hunter ZR; Yang G; Zhou Y; Cao Y; Liu X; Morra E; Trojani A; Greco A; Arcaini L; Varettoni M; Brown JR; Tai YT; Anderson KC; Munshi NC; Patterson CJ; Manning RJ; Tripsas CK; Lindeman NI; Treon SP Blood; 2013 Mar; 121(11):2051-8. PubMed ID: 23321251 [TBL] [Abstract][Full Text] [Related]
6. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177 [TBL] [Abstract][Full Text] [Related]
8. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations. King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639 [TBL] [Abstract][Full Text] [Related]
9. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Varettoni M; Arcaini L; Zibellini S; Boveri E; Rattotti S; Riboni R; Corso A; Orlandi E; Bonfichi M; Gotti M; Pascutto C; Mangiacavalli S; Croci G; Fiaccadori V; Morello L; Guerrera ML; Paulli M; Cazzola M Blood; 2013 Mar; 121(13):2522-8. PubMed ID: 23355535 [TBL] [Abstract][Full Text] [Related]
10. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Treon SP; Gustine J; Xu L; Manning RJ; Tsakmaklis N; Demos M; Meid K; Guerrera ML; Munshi M; Chan G; Chen J; Kofides A; Patterson CJ; Yang G; Liu X; Severns P; Dubeau T; Hunter ZR; Castillo JJ Br J Haematol; 2018 Feb; 180(3):374-380. PubMed ID: 29181840 [TBL] [Abstract][Full Text] [Related]
11. Detection of the MYD88 Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844 [TBL] [Abstract][Full Text] [Related]
12. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients]. Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092 [No Abstract] [Full Text] [Related]
13. Significances of MYD88 Meng Q; Cao XX; Li J Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839 [TBL] [Abstract][Full Text] [Related]
15. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863 [TBL] [Abstract][Full Text] [Related]
16. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557 [TBL] [Abstract][Full Text] [Related]
17. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474 [TBL] [Abstract][Full Text] [Related]
18. [The clinical features of patients with lymphoplasmacytic diseases harboring MyD88 L265P mutation]. Ren Y; Zhou BQ; Xu Y; Fu CC; Shen HJ; Ding ZX; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1054-1059. PubMed ID: 28088969 [TBL] [Abstract][Full Text] [Related]
19. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma. Mori N; Ohwashi M; Yoshinaga K; Mitsuhashi K; Tanaka N; Teramura M; Okada M; Shiseki M; Tanaka J; Motoji T PLoS One; 2013; 8(11):e80088. PubMed ID: 24224040 [TBL] [Abstract][Full Text] [Related]
20. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]